Clinical trialNCT00604383CompletedPhase 3Interventional

Protein Kinase C (PKC) Inhibitor-Diabetic Retinopathy Phase 3 Study

SponsorChromaderm, Inc.Enrollment685Diabetic Retinopathy

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study is to test whether or not 32 milligrams (mg) of ruboxistaurin a day over three years will reduce vision loss associated with diabetic retinopathy.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Karl Beutner
Chromaderm, Inc.
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

for Additional Information Regarding Investigative Sites for This Trial, Contact 1-877-Ctlilly (1-877-285-4559, 1-317-615-4559) Mon - Fri From 9 Am To 5 Pm Eastern Time (utc/gmt -5 Hours, Est) Or Speak With Your Personal Physician.
Indianapolis, Indiana, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

PlaceboRUBOXISTAURIN

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Mar 2001
Primary completion: 30 Jun 2005
Completion: 30 Jun 2005
Last update posted: 6 Oct 2016
Registered enrollment: 685
Registry id: NCT00604383

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.